Retatrutide has emerged as a new medication in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By stimulating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately contributes to significant weight loss